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In 2012 the UK media reported the results of a paper in the British Medical Journal Open, including the
ﬁnding that hypnotics increase the risk of ‘premature death’. Taking this media coverage as a case study,
the paper explores UK people's responses and assesses the implications for the debate about the (de)
pharmaceuticalisation of sleep. Two hundred and ﬁfty one posts to the websites of 6 UK newspapers
were analysed thematically, along with 12 focus group discussions (n ¼ 51) of newspaper coverage from
one UK newspaper. Four thematic responses were identiﬁed: bad science/journalism, Hobson's choice,
risk assessment and challenging pharmaceuticalisation. We found that most people claimed that the
story did not worry them, even if they stated that they were using sleeping pills, and that focus group
members generally appeared to respond in terms of their pre-existing views of hypnotics. The way in
which lay expertise was drawn on in responding to the coverage was one of the most striking ﬁndings of
the study. People referred to their own or others' experience of taking hypnotics to recognise the
legitimacy of taking them or to weigh up the risks and beneﬁts, as reﬂexive users. Overall, our case study
cautions against making strong claims about the power of the media to legitimate de-
pharmaceuticalisation. While the media may have such a role, this is in the main only for those who
are receptive to such a message already.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Sleep is in the news for all sorts of reasons these days. Scarcely a
day goes by without some sleep-related story appearing on life in a
‘chronically sleep deprived society’, from the stresses and strains of
living in a wired 24/7 world to excessive daytime sleepiness (Kroll
Smith, 2003; Seale et al., 2007; Williams, 2005; Williams et al.,
2008).
One important strand and long-running saga here concerns
media coverage of sleep medicines, particularly prescription hyp-
notics or sleeping pills, which have tended over time to receive a
bad press (Gabe and Bury, 1988, 1991, 1996a, 1996b). For example,
after a generally enthusiastic welcome in the 1960s, benzodiaze-
pine sleeping pills have been increasingly criticised for causing
addiction, dependence and even psychosis, and as examples of a
‘pill-popping way of life’ (Montagne, 1991).
In this paper we shed further critical light on thesematters, with
particular reference to debates on the (de)pharmaceuticalisation ofr Ltd. This is an open access articlesleep, taking recent media coverage of a British Medical Journal
Open article on the raised mortality risks of long-term prescription
hypnotics as our case study. In contrast to much previous work of
this kind, our focus here is on people's responses to this breaking,
newsworthy storyline, through online posts and follow up focus
groups. Key questions include the following: how did readers
process this story? did they feel more concerned about taking
sleeping tablets as a result of this news report, did they dismiss
such a report as an example of media exaggeration, and did they
respond according to their pre-existing views about the merits (or
otherwise) of taking such medications?
The paper, as such, is dually situated at the nexus of newly
emerging and long overdue attention to sleep matters in the social
sciences, medically related or otherwise, and other recent debates
in sociology and cognate ﬁelds regarding the ‘pharmaceuticaliza-
tion’ of life (Abraham, 2010; Williams et al., 2011; Bell and Figert,
2012), of which sleep of course is a vital part. Our focus in this
paper is on the extent to which media coverage of the negative
effects of sleeping tablets might contribute to the de-
pharmaceuticalisation of sleep. Before we consider our data on
this issue we review the literature on the pharmaceuticalisation ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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study.
2. The pharmaceuticalisation of sleep
Pharmaceuticalisaton has been employed as an explanatory
concept in the social sciences for some time, being ﬁrst used in
anthropology by Nichter in 1989 (cited in Bell and Figert, 2012) and
in sociology by Abraham in 2007 (Abraham, 2007; Gabe et al.,
2015). It refers to a process whereby human conditions, capabil-
ities and capacities are translated into opportunities for pharma-
ceutical intervention (Williams et al., 2011). While overlapping
with medicalisation (the use of pharmaceuticals as treatment is a
feature of both theories and both recognise that doctors can be
gatekeepers for medications) pharmaceuticalisation is distinct in
that it encompasses the non-medical use of pills (e.g. for lifestyle,
recreation or enhancement purposes) and access to them from
outside the medial arena (including over-the-counter purchases to
procurement on the Internet and black market). Relations between
pharmaceuticalisation and medicalisation are therefore complex
and contingent (Williams et al., 2011), especially in the case of
sleeping pills, which are predominately under medical control as
prescription medications.
A key conveyor or ampliﬁer of the process of pharmaceuticali-
sation, according to Williams et al. (2011), is the mass media who
may celebrate the introduction of new drugs, publicise particular
pharmaceutical regimes and generate various levels of public
support for their adoption (Biehl, 2007). For instance, as noted
above, the media in the US and UK gave benzodiazepine sleeping
pills an enthusiastic welcome as a new drug heralding a new era
when they ﬁrst arrived on the market in the 1960s (Gabe and Bury,
1996b). Similarly, others have found media coverage of new (can-
cer) drugs to be biased in favour of reporting beneﬁts, indeed
perhaps even overemphasising or exaggerating these, to the
exclusion of non-pharmaceutical therapeutic options (Davis, 2015).
However, once potential dangers in the form of side effects or
misuse have been detected, media coverage often takes a more
critical stance (Williams et al., 2011). Sleeping pills, particularly
benzodiazepines, have received a ‘bad press’ for many years, being
associated with side effects, dependence and addiction. The role of
the mass media in conveying processes of de-
pharmaceuticalisation through such ‘scare stories’ highlighting
dangers and risks associated with pharmaceutical use has not, to
our knowledge, been examined empirically to date.
While a major focus has been on the growth in pharmaceutic-
alisation, particularly in OECD countries, the process should be
viewed as bi-directional; in other words it is also possible for de-
pharmaceuticalisation to take place (Williams et al., 2011). For
example, doctors and/or patients/health consumer groups might
advocate a drug's withdrawal and replacement with non-drug
therapies, and this critical stance might be legitimated by the
mass media, as happened with the benzodiazepines in the 1980s
and 90s (Gabe and Bury, 1988, 1996b). While it is more likely in
practice for a new generation of drugs to replace a previous gen-
eration rather than being phased out as an area of intervention, the
latter remains a possibility (Gabe et al., 2015). And of course there is
evidence of resistance to pharmaceuticals and pharmaceuticalisa-
tion amongst lay people (e.g. Pounds et al., 2005; Murdoch et al.,
2013), who may demonstrate a sophisticated ‘lay pharmacology’
about the safety, efﬁcacy and side effects of prescribed medications
(Webster et al., 2009).
In the case of sleep there is considerable evidence that Britons
are suffering from sleep problems for which a medical solution
might be sought. It has recently been reported that up to one third
of Britons are suffering from insomnia at any one time, and that atleast one in ten can be characterised as a chronic insomniac (MHF,
2011). Having sleep problems also seems to be a persistent issue
with 74% in a longitudinal study reporting continuing problems one
year on and 46% claiming these difﬁculties three years on. In a UK
study of 17,000 respondents, one third reported that they had less
than 6.5 h sleep a night on average and 12% indicated that they
regularly had less than 6 h sleep a night (Understanding Society,
2011).
Faced with such sleep problems it is perhaps not surprising that
people have turned to doctors for advice and, as a result, have
frequently been prescribed a hypnotic. It has been reported that
around a tenth of people aged 16 and over take sleeping tablets
three or more times a week (9% men and 10% women) and the
likelihood of taking such a medication increases with age, although
varying by gender (Understanding Society, 2011). For example, in
the recent Understanding Society survey, 25% women and 15% men
over 85 years of age reported taking a hypnotic three ormore nights
a week, although this included both prescription and over-the-
counter medications. Interestingly, current rates of hypnotic pre-
scribing in the UK are less than theywere 35 years ago (13.6 million
prescriptions for hypnotics were issued in 1980, source: Morgan
and Clarke, 1997). While there was a marked increase in preva-
lence between 1993 and 2000, rates remained stable between 2000
and 2007 at around 10 million items prescribed per year (Calem
et al., 2012), although they have been declining a little more
recently (to around 9.5 million items in 2014, HSCIC, 2015).
The market for sleeping tablets in the UK has traditionally been
dominated by the benzodiazepines like temazepam and nitraze-
pam but these have now been replaced as market leaders by the so-
called Z drugs like Zopiclone and Zolpidem. In 2014 almost 6.5
million prescriptions for z drugs were dispensed (primarily Zopi-
clone) and nearly 2 million benzodiazepines were prescribed as
sleeping tablets (temazepam being the market leader with 1.7
million prescriptions) (HSCIC, 2015). The majority of these sleeping
tablets have been prescribed for four weeks or more; that is con-
trary to guidance from the UK National Institute for Healthcare
Excellence (NICE, 2004), which has consistently warned about the
dangers of dependence on these medications, especially the ben-
zodiazepines. Similar advice about the dependence potential of
benzodiazepines, including as sleeping tablets, was issued by the
UK Department of Health and Social Security in the 1980s (Gabe
and Bury, 1988).
Faced with such concerns, attention has been focused recently
on non-pharmaceutical treatments and whether they might be as/
more successful than medications. There is some evidence that
cognitive behavioural therapy (CBT) can be successful (Morin et al.,
1999, 2006) though this has still has to be endorsed by NICE,
through a national insomnia treatment programme, despite
lobbying for such guidance (NICE, 2010). CBT is also part of the UK
government's programme for Improving Access to Psychological
Therapies (IAPT) in England, suggesting that there has been some
modest encouragement for de-pharmaceuticalisation. However, as
the prescription rates suggest sleeping tablets still seem to be
favoured by many patients and their doctors.
This evidence of the use of hypnotics and the possibility of
alternative forms of therapy provides the context for our research
into the role the mass media play in the de-pharmaceuticalisation
of sleep. In our analysis we consider one aspect of this, namely, how
people respond to media coverage of the reported risks of hyp-
notics. In what follows we assume that audience readings of such
texts and/or reactions to them are made in relation to their bi-
ographies and the constraints of their daily lives; what Bloor (1995)
has called the situated rationality approach to risk. Responses are
likely to be diverse rather than uniform and may demonstrate
resistance as well as alignment with dominant ideas. Certainly
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about taking them, seeing them as representing an unnatural
interference with a natural state and associating their use with loss
of control and addiction (Cheung et al., 2015; Davy et al., 2013; Gabe
and Lipshitz-Phillips, 1984; Gabe and Thorogood, 1986; Venn and
Arber, 2012). Some users may thus respond to media coverage of
sleeping tablets as bolstering their resistance to taking these drugs,
while other users may reject the alleged risks of taking them and
continue to assert that they need them, while non-users may be
expected to take a more avowedly critical stance and accept the
risks of use as not only too great but as a sign of moral weakness. In
this way respondents are likely to draw on particular repertoires to
justify and legitimate hypnotic use/non-use in the management of
sleep problems such as the ‘deserving user’, the ‘responsible user’,
and the ‘addict’ (Gabe et al., 2016). By ‘repertoire’ we mean a
relatively coherent system of meanings for ‘characterizing and
evaluating actions, events and other phenomena’ (Potter and
Wetherell, 1987: 149).
Whatever their response it is assumed that audiences for such
messages should be seen as active rather than passive (Seale, 2004).
As Webster (2014: 120e1) argues, ‘audiences do not straightfor-
wardly absorb messages. Instead they interpret them, bringing to
them values and meanings gleaned elsewhere’. Moreover they
interact with these messages, to ‘challenge, expand, reject or
embrace’ them. This is certainly likely to be the case where people
have the opportunity to react online to what they have been
reading on the Internet.
3. Media case study and methods
We start with a brief account of the story and the media
response before discussing the methods we used to explore how
the public and focus group members responded to the story. The
value of the case study approach is also considered.
3.1. Media case study
On 28 February 2012 the UK media gave particular coverage to
an article in the British Medical Journal Open (Kripke et al., 2012)
about the negative effects of taking prescribed hypnotics. News-
papers, television news programmes and websites all reported the
study ﬁndings, often using eye catching headlines. This paper
considers how coverage of this news story on websites of UK na-
tional newspapers and the British Broadcasting Corporation (BBC)
resulted in a series of posts over eight days from the story's pub-
lication, and subsequently how members of focus groups viewed
such reporting. The ﬁndings are considered in the context of the
debate about the pharmaceuticalisation and de-
pharmaceuticalisation of sleep.
The BMJ Open article was based on a large study in the United
States which had compared medical records of 10,000 people who
had been prescribed sleeping pills over 2.5 years, on average, with
23,000 who reportedly had never received a prescription for such
drugs. Those prescribed sleeping pills, even at very low doses, were
found to be more likely to die than those who had not been pre-
scribed these pills. Those prescribed high doses (more than 132
pills a year) were alsomore likely to develop cancer than non-users.
Overall, however, the authors of the study admitted they could not
tell if the medicines themselves were a direct cause of higher rates
of death or cancer as it was possible that both the use of sleeping
tablets and the risk of death could be associated with lifestyle
factors.
UK newspaper coverage included a variety of headlines, ranging
from the broadsheets which noted ‘Safety concerns over sleeping
pills taken by millions' (Daily Telegraph) and ‘Sleeping pills increaserisk of death, study suggests' (The Guardian) through to tabloid
newspapers that claimed ‘Sleeping pill users “up to ﬁve times more
likely to die early”’ (Daily Mail) and ‘Sleeping pills can be lethal’ (The
Sun). On the BBC News website the headline was ‘Sleeping pills
“linked to increased death risks”’ (BBC News).
The Daily Mail article can be taken as an example of this media
coverage. It was chosen because it was accessible to all, unlike the
broadsheet articles, and had generated the most posts amongst the
tabloids. Although not directly advising hypnotic users to stop
taking this medication, this article can be seen as promoting a de-
pharmaceuticalisation agenda, focusing on the possible risks and
negative side effects of hypnotic medication whilst reporting non-
pharmaceutical alternatives to insomnia management (such as
CBTi) in a more favourable light. Concerned patients are then
advised to discuss their medication use with their GP. The article
ends with a short statement from a leading British expert in clinical
psychopharmacology who is quoted as saying “I agree these drugs
do have problems, but I ﬁnd some of these results difﬁcult to accept.
The main one is that with 18 doses a year you have three times the
mortality e that's quite incredible, because you would have people
dropping like ﬂies”.
Faced with these headlines how did audiences of the UK na-
tional media respond with online posts (referred to from this point
as ‘posters’) and how did those who were subsequently shown the
Daily Mail coverage in focus group discussions react? In particular
did they respond in such a way as to suggest that this coverage was
encouraging a process of de-pharmaceuticalisation?
3.2. Methods
Following the reporting of the BMJ Open paper in the online
version of the UK media on 28 February 2012, all posters' com-
ments linked to this coverage up to 6 March (eight days in total)
were included in the sample, totalling 293 comments. These posts
appeared on the websites of 6 newspapers (see Table 1).
Comments not directly relevant to the content of the newspaper
story (for example spam messages or arguments between posters
diverging from the content of the article) were excluded, reducing
the sample to 255 posters' comments. Exchanges between posters
were included where relevant. The sample incorporates occasional
multiple posts from the same user. It is not known exactly how
many people responded to these stories as they could have used
different user names to post messages. Nor is the background of
posters known, unless they revealed such information. It is possible
that some of the posters may have resided outside the UK as
geographical location was only mentioned by them infrequently. It
may also be the case that some posters wrote what they did in
order to appear knowledgeable in front of other posters rather than
express authentic feelings. The fact that most posters used pseu-
donyms makes such impression management less likely but does
not exclude it completely. Posters are also a self-selected group
although we do not see this as a problem given our case study
approach (see below). Analysis of the posts was undertaken
thematically, systematically identifying different topics in the data,
probing the disposition of the poster (whether favourable or hostile
to the storyline) (Bryman, 2012) and undertaking frequency counts.
In addition, an example of newspaper coverage of the story,
from the Daily Mail (described above), was discussed in focus
groups with people who might be expected to have particular
views on sleep and its management. We purposively selected these
groups in order to explore diversity in experiences of and attitudes
towards sleeping pills rather than for representativeness. The focus
group was chosen as the preferredmethod as wewere interested in
how people discussed sleep and sleeping pills collectively and the
normative understandings underlying such processes (Bloor et al.,
Table 1
Readers' posts by media outlet (28 February e 6 March 2012).
Newspapers:
Tabloids
Daily Mail 62 posts (61 individuals)
Daly Express 6 posts (5 individuals)
Sun 21 posts (19 individuals)
Broadsheets
Daily Telegraph 41 posts (28 individuals)
Guardian 115 posts (102 individuals)
Independent 11 posts (7 individuals)
BBC News online 0 post
Total number of posts 256 (222 individuals)
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participant's point of view is much more likely to be revealed than
in a traditional interview, because s/he has more ownership of the
research process. On the other hand there are potential problems
with ‘group effects’, especially whether group norms lead to more
agreement than one might expect to be the case (Morgan, 1997)
and the possibility that participants may be prone to expressing
culturally expected views (Bryman, 2012). In the study reported
here the pressure to express expected views about the media story
may have beenmoderated by the scheduling of this topic late in the
focus group, when impression management might have been less
of an issue.
Following ethics approval from the National Health Service in
England, we held 12 focus groups with 51 participants between
2012 and 2014 who discussed the Daily Mail article (a further
eleven groups did not consider the article). Focus groups ranged
from those recruited from primary care who had been long term
users of hypnotics (3 focus groups, 12 participants) to residents of a
retirement complex (3 focus groups, 15 participants) to parents of
young children (one group, 6 participants). Focus groups were also
held with medical students (one focus group, n ¼ 3), university
lecturers (two focus groups, n ¼ 8), lawyers (one group, n ¼ 3) and
those suffering fromnarcolepsy (one focus group, n¼ 4). The size of
the group did not seem to have any bearing on the content of the
talk generated.
Research participants were recruited in a number of ways.
General practice patients were invited to participate by their GP, on
the basis of having received a prescription for sleeping tablets.
Those attending the narcolepsy clinic were asked to contact the
researchers if they were interested in being part of the research by
the clinician in charge of the clinic. Students were recruited
through the local university student union, departmental student
lists and personal contacts. Parents of young children were
recruited through local parent and toddler groups. The focus groups
made up of academics and lawyers were formed through personal
contacts. Those who lived in the retirement complex were invited
to participate via a gatekeeper who lived on site. All participants
were given an information sheet in advance, explaining that their
comments would be anonymised and that they could withdraw
from the study at any time without giving a reason. Written
informed consent was provided by all participants.
The resulting 12 focus groups were reasonably diverse in terms
of age, with about 55% of the sample being 45 years of age or over.
Around 70% of participants were female and over 90% identiﬁed as
of white British or Irish ethnicity. Over half the sample (60%) had, or
had previously had before retirement, a higher managerial or
professional job (see Table 2).
In each of these focus groups we asked participants to discuss
how they managed sleep problems in their daily lives, including
whether they used hypnotics, as well as their views of the news-
paper story. Towards the end of each focus group session we
handed out the media story to participants and asked them to look
at it and tell us what they thought. Thirty one participants, across
the 12 focus groups, disclosed current or previous use of pre-
scription hypnotic medications. Of these almost three quarters
were members of the primary care or retirement complex focus
groups. Not surprisingly it was those from the primary care and
retirement complex focus groups who were the ones who could
remember having read or heard reports of the BMJ Open paper in
the media.
Focus groups were audio recorded and transcribed. Analysis of
the transcripts was facilitated using the qualitative data analysis
software package NVivo 10. We took an inductive approach to data
analysis, which involved reading and re-reading the transcripts,
grouping data extracts together based on the main themes anddeveloping a coding frame based on these emergent themes to
identify major topics and issues. Codes and themes relating to
major issues were discussed between the authors for purposes of
reliability and validity. These were used to develop an interpreta-
tive analysis of the meaning of the newspaper coverage about the
BMJ Open article and to address the research questions outlined
above.
Subsequently each focus group member was given an identi-
fying code, indicating the type of focus group they had participated
in, the number of the group and the gender of the participant, and
the sequence in which they ﬁrst spoke in the focus group (for
example, PCFG1F1 indicates Primary Care Focus Group 1, Female 1).
We have chosen a case study approach as it is useful in exem-
plifying ‘the circumstances and conditions of an everyday or
commonplace situation’ (Yin, 2009: 48). In our case the common-
place situation is how people reacted to the media story about the
negative effects of sleeping tablets. The case study approach also
provides a suitable context for addressing our research questions
(Bryman, 2012). No claim is being made for the representativeness
of the posters and focus group members. Rather ‘the validity of the
extrapolation depends … on the cogency of the theoretical
reasoning’ (Mitchell, 1983: 207) and the extent to which the data
support this reasoning.
Finally we should mention two limitations of our study before
proceeding. First it should be noted that while we have a baseline
understanding of how focus group members thought about hyp-
notics before reading the news report, as they had already
expressed their views about these pills before being introduced to
the coverage in the Daily Mail, this is not the case with the posters.
We do not knowwhat they thought of sleeping pills before posting
their comments online. Second, it is possible that there were
readers of the news report who accepted its de-
pharmaceuticalisation framing but decided not to post. Those in-
dividuals who did not post their thoughts after reading the article
may be the ones most likely to have felt they had ‘learned’ some-
thing or accepted the articles' general stance and content whilst
those disagreeing might have been more motivated to put their
alternative viewpoint across. It is impossible to know whether this
was so as we only have data from posters, but there were a sizeable
number of such posters who did embrace this de-
pharmaceuticalisation framing. Below we consider posters and
focus group members' reaction to this media story in terms of
different responses.
4. Reactions to the media story online and in focus groups
Four main responses were employed by people in posts or focus
group discussions when assessing the media coverage of the BMJ
Openpaper. Thesewere: i) To dispute the validity of the information
presentede by claiming that it illustrated what we have called ‘bad
science/journalism’; ii) To emphasise the crucial role that hypnotics
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sense they had no choice but to use hypnotics e Hobson's choice;
iii) To assess the risks and beneﬁts of using sleeping tablets,
reﬂecting a range of views around risk avoidance and risk taking;
and iv) To elaborate the negative message of the media reporting
and/or suggest non-drug alternatives. Participants variously called
on repertoires of the ‘deserving user’ (in distress and in need of
help), the ‘responsible user’ (who used their medication appro-
priately) and the ‘addict’ (whowas escalating use and losing control
over their medication and themselves) in their response to the
media story (Gabe et al., 2016). Posters were assigned to only one of
these responses on the basis of their posts, as were the great ma-
jority of focus group members given their comments.
Beside the four major themes outlined here 37 posts were on
other topics. Some focused on sleep and lifestyle with sleep being
seen as a virtue. Posters talked about how important sleep was and
how lifestyle factors such as stress, diet and exercise can affect sleep
either negatively or positively. Other posts were concerned with
clariﬁcations or corrections, for example about safety issues or
regulation or contained criticisms of other posters for the stance
they had taken. No other themes were mentioned in the focus
groups.
Below we consider the four main responses in turn.4.1. i)‘Bad’ science/journalism
This represents the biggest category of posts (n ¼ 70) and
comments by focus group members (n ¼ 26). Interestingly posters
often sought to develop a sophisticated methodological critique of
the study published in the BMJ Open as ground for questioning the
validity of the ﬁndings. Some recognised that a correlation was not
the same as causation or that hypnotic drug use was best seen as a
proxy for an underlying ‘disease state’. Others saw the coverage as
reﬂecting a failure by journalists to take a critical stance and
interrogate the statistics, resulting in scare mongering.Table 2
Medicated sleep: participant demographics.
Focus Groups Number of
participants
Gender (M/
F)
Age range Ethni
Academics
2 groups (AFG1 -2)
8 3F
5M
25e54 7 WB
1mix
Lawyers
1 group (LFG1)
3 2F
1M
35e44 2 WB
1 Wh
Narcolepsy Patients
1 group (NFG2)
4 2F
2M
18e54 4 WB
Parents of Young
Children
1 group (PFG1)
6 6F 25e44 4 WB
1 Asia
1 Wh
Primary Care Patients
3 groups (PCFG1 -3)
12 6F
6M
45-85þ 12 W
Retirement Complex
3 groups (RFG1 -3)
15 14F
1M
65-85þ 15 W
Students
1 group (SFG4)
3 3F 18e34 3 WB
Totals 51 36F
15M
18-24 (3)
25-34 (8)
35-44 (8)
45-54 (8)
55-64 (4)
65-74 (4)
75e84(12)
85þ (3)
Not disclosed
(1)
47 W
2 Wh
1 Asi
1 MixFor example, consider a post on The Guardian website:
‘Hypnotics represent a valuable aid to individuals during times
of distress. Disrupted sleep is one of the commonest symptoms
complained of by those with depression. Those with physical
conditions in general hospital often request sleeping aids as
well. This case controlled study makes no attempt to control for
mental state, or disease severity, so disrupted sleep, requiring
hypnotic prescription, could just indicate disease severity, or a
co-morbid mental health problem, both of which could also
raise mortality’.
The complex nature of this critiquemakes onewonder about the
background of the posters and the extent to which they had a
vested interest in the prescribing of sleeping tablets.
In comparison with the above, focus group members were
generally less sophisticated in their comments and focused pri-
marily on the sensationalist nature of reports in the tabloid
newspaper running the story and their lack of trust in the story as a
result. The focus on sensationalism is not perhaps surprising given
the nature of tabloid coverage (Seale, 2002), yet even the Daily Mail
provided readers with enough information about risk to make an
assessment of the validity of the claim. In some cases the lack of
trust reported was linked to the focus group members' view that
statistics can be manipulated.
‘Well the ﬁrst thing, just looking at this … I don't believe any-
thing the Daily Mail says. And sleeping tablets, “you are ﬁve
times more likely to die early” … Five times more likely than
what? I mean statistics, anything like that. I would just question
what it means. I wonder howmuch of it is selective by the Daily
Mail because a number of times I've got things from the Daily
Mail that are just plain wrong… If it had been (the broadsheet
papers) The Times, The Guardian, The (Daily) Telegraph even, I
think I might make a bit more of it. But I don't believe anything
from the Daily Mail.’ (Primary Care FG3, Male 1)city SES Number taken
hypnotics
/Irish
ed (White&Asian)
8 Higher Managerial & Professionals 2
/Irish
ite (other)
3 Higher Managerial & Professionals 2
/Irish 3 Intermediate
1 Unemployed
3
/Irish
n or AB (Pakistani)
ite (other)
5 Higher Managerial & Professionals
1 Intermediate
1
B/Irish 6 Higher Managerial & Professionals
1 Intermediate
3 Technical & Craft
2 Not disclosed
12
B/Irish 9 Higher Managerial & Professionals
3 Intermediate
3 Technical & Craft
10
/Irish 3 Students 1
B/Irish
ite (Other)
an/Asian British
ed
31 Higher Managerial &
Professionals
8 Intermediate Occupations
6 Technical & Craft
3 Students
1 Unemployed
2 Not disclosed
31
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or mentioned the distinction between cause and correlation but
seemed to lack the degree of statistical knowledge demonstrated
by the posters. Consider, for example, the comment of a participant
in an academic focus group:
‘The fact that it is in the Daily Mail does framemy reaction… the
impression I get is science reporting, even in publications that I
read like the Guardian, is not great. I'm not a trained scientist but
I'm vaguely aware of issues of correlation and cause and
listening regularly to the (BBC) Radio Four programme about
statistics, I'm aware of how a small quirk in analysis can actually
create the impression. This phrase at the end [from a leading
expert in clinical psychopharmacology] about, well you know, if
that was the mortality rate people would be ‘dropping like ﬂies’
precisely suggests that phrases like ‘ﬁve-fold increase’ and so on
are misleading. They might be technically correct but I think
there is a sort of general default position which is that every
given day a newspaper, especially the Daily Mail, will blame
something for cancer … So actually I would be quite relaxed I
think. I mean I'm not on any medication but I think that I would
actually take this as an unnecessarily alarmist treatment of
research which seems relatively inconclusive.’ (Academic FG 1,
Male 1)
This respondent was clearly sceptical of media reporting in
general, and in the Daily Mail in particular, and used his limited lay
knowledge of statistics, itself informed by a radio series, to justify
dismissing the story as unnecessarily alarmist. As he illustrates,
such views were not limited to those taking hypnotics but reﬂect a
general scepticism of people about the validity of the claims in the
media, including in the tabloids. This response reﬂects what Collins
(2014) has described as ‘ubiquitous meta expertise’, using logic
rather than technical knowledge to challenge a media story.
As we also see in the extract above, it was common for those
rejecting the content of the article to connect with and repeat the
expert in clinical psychopharmacology's quote that should the
statistics presented be accurate, people would be ‘dropping like
ﬂies’. It is interesting how those taking this stance accepted the
reporting of a statement by one expert, as it afﬁrms their own
stance or beliefs (regarding the publication, the medication or the
statistics), while the presentation of research ﬁndings of others are
questioned or rejected. We can see here then, how readers are both
active and selective in their processing of media information.4.2. ii) Hobson's choice
For posters in this category (n ¼ 36) sleeping tablets were not
just beneﬁcial, theywere crucial in helping them to keep going or in
some cases simply enabling them to survive. In developing this
viewpoint they drew on experiential knowledge and the repertoire
of the ‘deserving user’ (Gabe et al., 2016). For them going without
these drugs would make them ‘go crazy’. Some combined an
emphasis on the drug enabling them to survive with the beneﬁts
for public safety and for society. By taking sleeping tablets and
acting as ‘responsible’ users they avoided the risk of an accident and
were able to hold down a job. In the latter case public health
messages about responsibilization (Rose,1999) were being inverted
and used to justify taking pills regularly, in contrast to the advice of
bodies such as NICE.
Take, for example, the following post in The Guardian:
‘As a chronic insomniac for over 25 years I have been on and off
sleeping tablets for years, been to sleep clinics, had CBTand triedalmost everything on the market. I can go for days without sleep
which is unbearable for myself, colleagues and family as it has
caused me to have constant depression and anxiety. I do not
drive due to the effects of Zolpidem which is a pain but, if my
little white pill (half now as I have cut down) helps me to
function on a daily basis, hold down a job and live a relatively
normal life and my life is cut short because of it, so be it.
Tiredness is more of a killer in my view.’
We see here how non-pharmaceutical treatments are
acknowledged, the poster has ‘been to sleep clinics’ and ‘had CBT’,
and subsequently dismissed as a viable alternative to the phar-
maceuticalisation of sleep.
Such meanings were present but found to a much lesser extent
in focus group discussions of the newspaper report. The example
below comes from one of the retirement home focus groups where
the participant draws on the repertoire of the ‘deserving user’ in
arguing that hypnotics had an important role in themanagement of
sleep problems for those who were desperate, as follows:
‘You've got to think of the effect that insomnia has on a person's
family. I mean if you have got someone walking the street or
walking the ﬂoor all night, when they don't live on their own,
because they can't sleep, I mean it's very disturbing to put it
mildly. So there's a place for them’. (Retirement FG 3 Female 2)
Thus posters and focus group members who emphasised the
necessity of sleeping tablets in response to the media coverage of
the BMJ Open article were in effect resisting the de-pharmaceutical
agenda being supported in such coverage.4.3. iii) Risk assessment
In addition to talk about resisting, rebufﬁng or questioning de-
pharmaceuticalisation there was also discussion of the risks as
well as the beneﬁts of sleeping tablets. Posters employing this risk
language (n ¼ 66) talked freely about particular hypnotic drugs
they had used and gave advice about them. As such they could be
characterised as offering a risk/beneﬁt analysis, in line with
Webster et al.'s (2009) concept of ‘lay pharmacology’. For some the
risk was worth taking whereas for others it was too risky. This
group thus contained both those who were supportive of phar-
maceuticalisation and others who were in favour of de-
pharmaceuticalisation or at least restricting pharmaceuticalisation.
Below are examples of an exchange between posters which
illustrate both positions, starting off with one who felt the risks
were worth taking, drawing on the ‘deserving’ repertoire. The
second poster takes the opposite position, drawing on an ‘addic-
tion’ repertoire and advocating limited use at best:
‘Another scare story youwould expect to ﬁnd in the Mail! I have
had trouble sleeping for years. I've tried everything. The only
thing that works for me is a mild German tablet called Lend-
ormin. Perfect! I have regular check-ups (blood etc.) and
everything is OK. Anybody else had any experience of this
particular life saver?’
‘Brotizolam (aka Lendormin) is not licensed in the UK e or the
USA. It's not particularly mild, some class it as one of the
strongest benzodiazepines around e hence the lack of a license
here. Even in Germany it should only be used for severe
insomnia and short term e only 2e4 weeks. Otherwise you are
addicted. Oh dear… ’ (Daily Telegraph)
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(n ¼ 13) when discussing the media report and, like the posters,
generally fell into one of two camps having weighed up the risks, as
supportive of or rejecting sleeping pills. Amongst those who saw
the beneﬁts as greater than the risks were those on hypnotics from
the residential home who considered that at their time of life what
was the point of taking them off these pills if their quality of life was
damaged as a result. For example, consider the following exchange
amongst focus group members:
RFG1F6:… doesn't it matter at our age?
RFG1F1: Exactly it's like telling a 99 year old to stop smoking.
RFG1F3: Yes, change your diet? Why?!
RFG1F6: I'm not being morbid. I'd rather go early with a good
life, feeling good.
RFG1F7: There's not much sense to living to 95 if you feel awful,
isn't it?
Moderator: So you actually said you had seen this (news story)
before. When you saw it what did you think?
RFG1F7: I'd turned my back on it actually, at my age. Probably if
you were younger you might take more notice of it but it didn't
impress me … It didn't worry me that I would be popping my
clogs earlier… I'd read everything that's available and you just
make your own judgement then, don't you.
As we can see the message of the media story was also dis-
counted on the grounds of ‘age’ and ‘lay expertise’. Other focus
group members who were not hypnotic users were more willing to
accept the message of the media story, taking a more negative view
of the risks in light of the contents of the newspaper article’. For
example:
‘I think it's very serious. I didn't realise it was as bad as that, you
knowwhen you read it. It's worrying, isn't it for people that take
a lot of them… If I was on any of these, my God I'd be there (GP's
surgery) tomorrow (to discuss the risks)!’ (RFG2F4)
We can see in the above example how media coverage of
medicines could perhaps contribute to a wider ‘de-pharmaceutic-
alisation’ agenda, by highlighting risks and inciting concern around
the use of particular pharmaceutical products. In this case, how-
ever, awareness of the risks did not undermine trust in medical
authority. Rather, the GP was seen as potentially a key source of
advice.4.4. iv) Challenges to pharmaceuticalisation
A fourth and ﬁnal group of posters (n ¼ 47) took a markedly
more critical stance. They aimed their criticism at both GPs for
handing out hypnotics too easily and at the drug companies who
they felt were primarily concerned with proﬁt maximisation. Take,
for example, a poster from the Guardian who opposed pharma-
ceutical solutions to health problems, including sleeplessness:
‘Prescription drugs kill a lot of people in the USA every year. This
is only the tip of the iceberg. The culture that has doctors
reaching for their prescription pads for absolutely every real or
imagined ill is long overdue a serious overhaul.’
Other posters aligned themselves with a de-
pharmaceuticalisation agenda in recommending alternatives to
hypnotics. These included herbal remedies, cognitive behaviour
therapy (CBT) and even salt water. For example:‘Sleep experts say most mental illness is due to lack of, and poor,
sleep. To get the sleep you get at the coast when the wind blows
in from the sea, just heat salt water in an oil burner overnight.
This cures insomnia in just ﬁve nights, and takes with it any
symptoms of mental illness.’ (The Sun)
Occasionally a poster would express desire for de-
pharmaceuticalisation of their own sleep but also the difﬁculty in
achieving this without wider support for and access to non-
pharmaceutical treatments such as CBT. The poster below ex-
presses exasperation for being refused CBT by a GP as an alternative
to sleeping pills. While being critical of this state of affairs, sleep-
lessness was still being deﬁned in medical terms as a problem that
medicine might help alleviate:
‘I returned to the doctors in January this year (after having
previously been prescribed temazepam and Zopiclone) and
asked about CBT (Cognitive Behavioural Therapy) as I don't want
to spendmy life on sleeping pills… This was refused point blank
- my doctor didn't even seem to be aware it was a valid option
for insomniacs, saying it was only for depression.’ (The
Guardian)
Focus group members who challenged pharmaceuticalistion
(n ¼ 7), in contrast, were somewhat less critical and generally
restricted themselves to claiming that the media coverage
conﬁrmed their view that prescriptions for sleeping tablets were
too readily available from GPs and that, if they were still users, such
coverage provided themwith an increased incentive to stop taking
the tablets. Consider the following exchange between a male and
female participant from a primary care focus group and the group
moderator:
PCFG2M1: I think this is going to… just increase my incentive to
get off these drugs by the end of the calendar year basically.
Deﬁnitely I know, because of the way I feel that taking Zopiclone
isn't good for my body. So I've got to go with that.
Moderator: You had already heard the news story, did it stim-
ulate you into checking it out any more at the time?
PCFG2M1: Well I spoke to a friend who worked, until recently
with mental health services… and had a chat with her about…
Moderator: As a result of this news story?
PCFG2M1: Yes, as a result of the news story and she said ‘I don't
know howmany people are prescribed Zopiclone in this country
but I bet it is millions'. I didn't knowwhat the ﬁgurewas but I do
now. I'm shocked actually, that it’s that high. She said a lot of this
medication shouldn't be prescribed in the ﬁrst place and if it is
should be very, very strictly monitored. A lot more should be
done so that people don't end up being addicted.
Later in the discussion he continued:
PCFG2M1: We probably all know that a little bit of something
doesn't tend to have a lasting harm. I'm not doing a little bit of
Zopiclone, I'm doing it every day for years … So I've got to do
something about it.
PCFG2F1: But print, actually having it in print, black and white,
changes your attitude to the way you think, sometimes as well.
So I mean, I would be … I could still go on for years and years
and not be bloody questioned by my doctor, but because I've
seen that perhaps I'll question her now. But then I'm only on a
small dose.
In this case the male focus groupmember had already heard the
story and said he had conﬁded with a friend with clinical experi-
ence who reinforced the negative message that sleeping tablets
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tients getting addicted. The ‘addiction repertoire’ was thus
employed rhetorically to support his claim that he intended to
come off sleeping tablets as soon as possible. His view was
endorsed by a female member of the focus group who said that the
media story had changed her mind and made her think about
raising it with her GP, thus continuing to rely on medical authority,
although she wanted to make it clear she was not a heavy user (and
by implication not addicted). This is the only case in our two data
sets where the media coverage of sleeping pills could be said to
have challenged people's world view and made them re-think,
perhaps because there was a degree of consensus, in light of the
media story, that withdrawing from long term hypnotic use was
advisable.
Interestingly, none of the focus group participants were critical
of the pharmaceutical companies who made the sleeping tablets
and only one group talked about cognitive behaviour therapy as an
alternative but dismissed this on cost grounds, as reﬂected in the
following exchange:
PCFG2M2: If they were to switch to this CBT… that costs more
than pills…
PCFG2M1: Someone is asking that question somewhere I guess.
PFG2M2: If it costs more they won't change, will they?… They
will be spending more money when they're supposed to be
reducing … there is only so much pie, isn't there?
Here the possibility of de-pharmaceuticalisation through CBT is
therefore considered but seen as unrealistic for economic reasons.
This is in contrast to the poster above who reported being denied
CBT by his GP. In both cases de-pharmaceuticalisation via CBT is
seen as problematic.
5. Discussion
This paper has considered how a story about the long term risks
of taking prescribed hypnotics ﬁrst reported in the BMJ Open and
then on websites of English national newspapers and the British
Broadcasting Corporation was responded to through online com-
ments (posts), and subsequently by members of focus groups. The
paper is thus concerned with what some have called ‘short-term’
rather than ‘long-term effects’ of media coverage (see, for example,
Hernandez et al., 2012 for such a distinction).
Overall we found that the dominant message of the media
coverage of this story - that hypnotics enhance the risk of ‘pre-
mature death’ - did not seem to create alarm on the part of the
different audiences. In the case of focus group members they
generally appear to have responded in linewith their existing views
of hypnotics. As acknowledged previously, we are not able to make
this claim about the posters as we do not know how they viewed
sleeping pills before the press coverage of the BMJ Open article.
This is not to say that the people in our study were all passive
recipients of media reports. On the contrary, as we have seen, there
was strong evidence of resistance to the media story amongst some
posters and focus group members. This took the form of criticising
the reporting of the story as evidence of ‘bad’ science/journalism,
continuing to claim that hypnotics were a necessity despite con-
cerns reported in the media (a view expressed by users as far back
as the early 1980s (Gabe and Lipshitz-Phillips, 1982)) and drawing
on lay knowledge and experience (Williams and Popay, 2006) or lay
pharmacology (Webster et al., 2009) to justify continued use.
Repertoires such as the ‘deserving user’ and the ‘responsible user’
were called on to justify continued usewhile that of the ‘addict’was
drawn on to support withdrawal from use or non-use (Gabe et al.,
2016). There was indeed only one case where focus groupmemberswho were on hypnotics expressed a desire to withdraw or at least
discuss that possibility with their doctor in light of the media story,
perhaps reﬂecting a degree of consensus in the group about the
merits of de-pharmaceuticalisation in the face of addiction.
The extent to which lay ‘expertise’ was drawn on in responding
to the media story was one of the most striking ﬁndings of this
study. People drew on their own or others' experience of taking
hypnotics to recognise the legitimacy of taking them or to weigh up
the risks and beneﬁts in true late modern style, as reﬂexive users
(Williams and Calnan, 1996). Posters in particular expressed scep-
ticism about the scientiﬁc quality or methodological limits of the
study and the difference between association and causation,
apparently drawing on ubiquitous meta-expertise (Collins, 2014).
They were however a self-selected group which might explain in
part at least the availability of such expertise. It is also possible that
some of themwere not lay experts at all however, but scientists and
experts of various kinds in their own right. Which would explain
the more sophisticated methodological critique of some of the
posters, although again we have no concrete evidence to suggest
that this was so.
In terms of the wider issue of (de)pharmaceuticalisation, stories
such as the one considered here can be seen as contributing to the
de-pharmaceuticalisation of sleep agenda that has been emerging
in the UK, with measures being put in place to reduce hypnotic
prescribing in primary care and some encouragement of CBT from
the UK government through the IAPT programme. By framing the
story in terms of the risks involved in taking sleeping pills the
media may be able to raise public awareness of concern about
them. In generating awareness of CBTas an alternative to hypnotics,
de-pharmaceuticalisation of sleep is being promoted as a realistic
possibility. This could be of particular signiﬁcance given that a lot of
people now get health related information directly from the media,
online or through traditional media outlets (Broom and Tovey,
2008; Nettleton, 2004; Seale, 2004), rather than from doctors.
At the same timewe have seen that recipients of themedia story
about sleeping tablets were active and selective in their response to
coverage of this issue, as one might expect given the literature on
media audiences more generally (Seale, 2004; Webster, 2014). In
this case we found that they often reacted in line with existing
views and values, drawing on ubiquitous meta expertise (Collins,
2014) or experiential/lay knowledge to corroborate or rebuff in-
formation made available to them; thereby in the process sup-
porting pharmaceuticalisation or encouraging its reduction. This
ﬁnding is similar to other research on people's responses to health
stories, such as that concerning online commentators' reaction to
media stories challenging US guidelines on breastfeeding (Holton
et al., 2014; Len-Rios et al., 2014). Consequently, it seems that
negative stories aboutmedications are not necessarily translated by
people intomessages to stop taking them or encouragement for de-
pharmaceuticalisation. In our study there was only one occasion
where this was so, but even then, the subsequent focus group
discussion may have been more inﬂuential in encouraging the
hypnotic user to consider cessation of the pills.
Despite the media in this case presenting CBT as a non-
pharmacological alternative to sleeping pills, thus making de-
pharmaceuticalisation seem a realistic possibility, we found that
when non-drug therapies like CBTwerementioned readers focused
on the problems of access or effectiveness rather than seeing them
as a realistic alternative to drugs. Moreover, access to therapy was
still through doctors, thereby suggesting that it is possible to have
the promotion of de-pharmaceuticalisation alongside continuing
medicalisation. Further evidence for the continuation of medical-
isation in the face of potential de-pharmaceuticalisation is provided
by those focus group members who said that negative media
coverage of sleeping tablets might lead them to seek advice from
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In sum, our case study cautions against making strong claims
about the power of the media in encouraging or promoting de-
pharmaceuticalisation. As Williams et al. (2011) note, the mass
media may be considered as ‘conveyors’ or ‘ampliﬁers’ of phar-
maceuticalisation, rather than drivers of the process. The media's
negative framing of the hypnotics was generally interpreted in line
with readers' existing values, with the negative messages either
being endorsed or challenged in line with their particular world
view and non-pharmaceutical alternatives critically assessed rather
than being unquestionably accepted as legitimate replacements for
hypnotics.
This might go some way to explaining why, despite years of
negative media coverage around sleeping pills, ambivalence about
their use and evidence of widespread reluctance to take them in the
general population (Gabe et al., 2016), rates of use have remained
relatively static. Media reporting on the risks and dangers of hyp-
notic use may strongly communicate and proliferate an anti-
pharmaceuticalisation message. However, unlike media stories of
new wonder drugs that promote pharmaceutical expansion and
others which might fall under the umbrella of ‘disease mongering’
(Moynihan, 2002), in cases of de-pharmaceuticalisation, the mes-
sage is really only relevant to those whose sleep is already, or has
been, pharmaceuticalised. These groups are therefore likely to hold
pre-existing views regarding hypnotic use based on experiential
knowledge and as our data suggests react to media stories in line
with these views. Our analysis suggests that while the media may
have a role as legitimators of de-pharmaceuticalisation, this is in
the main only for those who are receptive to such a message
already.
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